Company news

Lyell Immunopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

November 8, 2023

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

November 6, 2023

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

October 30, 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 26, 2023

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

September 10, 2023

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

September 10, 2023

Lyell Immunopharma to Participate in Upcoming Investor Conferences

August 30, 2023

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

August 7, 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

July 4, 2023

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 3, 2023

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

May 1, 2023

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

February 27, 2023

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

December 14, 2022

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

November 30, 2022

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

November 9, 2022

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

November 7, 2022

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

November 6, 2022

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

November 1, 2022

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

October 5, 2022

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 4, 2022

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

September 27, 2022

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

September 11, 2022

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

August 29, 2022

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

August 3, 2022

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

June 6, 2022

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

May 9, 2022

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

May 1, 2022

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

March 28, 2022

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

March 7, 2022

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

January 30, 2022

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

January 23, 2022

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

December 15, 2021

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

December 14, 2021

Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair

December 1, 2021

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

November 11, 2021

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

August 11, 2021

Lyell Immunopharma Announces Pricing of Initial Public Offering

June 15, 2021

← Newer news releases

Decks

The 5 newest of 6 decks. Every deck is listed under its year.